Daniel Pratt is a Gastroenterology physician affiliated with Harvard University. OpenAlex indexes 96 publications with 5,398 citations (h-index 30); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Blk 4
Boston, MA 021142621
Telephone
617-726-3313Registry record last updated 14 Dec 2012.
Clinical trials
- The INSPiRe Programme: Developing an Intensive Suicide Prevention Therapy for Suicidal Prisoners
Sponsor: University of Manchester
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ipsen Biopharmaceuticals, IncProgram year20256 payments$24,175openpaymentsdata.cms.gov ↗
- Perspectum Diagnostics LtdProgram year20251 payment
- Gilead Sciences, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
68.2%Bile Acid47.5%Ursodiol100%Part D≥106 patientsBile acids and derivatives5.8%Ocaliva100%Part D<11 patients+ 5 more classes in this area
Cancer & immunology
14.5%Purine Antimetabolite8%Azathioprine100%Part D≥20 patientsCalcineurin inhibitor6.5%Tacrolimus100%Part D≥14 patientsAnti-infectives
7%Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor2.8%Entecavir100%Part D<11 patientsNucleoside and nucleotide reverse transcriptase inhibitors2.2%Vemlidy100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”